风车车
Lv2
110 积分
2022-02-18 加入
-
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
16小时前
已完结
-
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial
16小时前
已完结
-
Psoriasis
2天前
已完结
-
Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (‘clinical super response’): Week 28 results from the ongoing phase IIIb randomized, double‐blind, parallel‐group, GUIDE study
2天前
已完结
-
Disease modification in inflammatory skin disorders: opportunities and challenges
2天前
已完结
-
Paradoxical eruptions to targeted therapies in dermatology: A systematic review and analysis
9天前
已完结
-
微小病变肾病的发病机制及治疗研究进展
10天前
已关闭
-
A novel approach to induce early remission in high-risk primary membranous nephropathy
10天前
已完结
-
Incorporating Evidence and Guidelines for Personalized Care of Diabetes and Chronic Kidney Disease
25天前
已完结
-
Albuminuria and cardiorenal risk
25天前
已关闭